1. Home
  2. ETON vs TPVG Comparison

ETON vs TPVG Comparison

Compare ETON & TPVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eton Pharmaceuticals Inc.

ETON

Eton Pharmaceuticals Inc.

HOLD

Current Price

$16.83

Market Cap

498.8M

Sector

Health Care

ML Signal

HOLD

Logo TriplePoint Venture Growth BDC Corp.

TPVG

TriplePoint Venture Growth BDC Corp.

HOLD

Current Price

$6.32

Market Cap

254.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETON
TPVG
Founded
2017
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
498.8M
254.1M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ETON
TPVG
Price
$16.83
$6.32
Analyst Decision
Strong Buy
Hold
Analyst Count
3
6
Target Price
$29.67
$6.38
AVG Volume (30 Days)
233.1K
436.0K
Earning Date
11-06-2025
11-05-2025
Dividend Yield
N/A
14.56%
EPS Growth
N/A
208.85
EPS
N/A
0.84
Revenue
$70,316,000.00
$93,623,000.00
Revenue This Year
$107.23
N/A
Revenue Next Year
$29.72
$7.50
P/E Ratio
N/A
$7.49
Revenue Growth
102.77
N/A
52 Week Low
$11.09
$5.24
52 Week High
$23.00
$8.20

Technical Indicators

Market Signals
Indicator
ETON
TPVG
Relative Strength Index (RSI) 53.73 51.30
Support Level $16.27 $6.02
Resistance Level $16.95 $6.44
Average True Range (ATR) 0.64 0.18
MACD 0.16 -0.05
Stochastic Oscillator 75.95 38.58

Price Performance

Historical Comparison
ETON
TPVG

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

About TPVG TriplePoint Venture Growth BDC Corp.

TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.

Share on Social Networks: